• Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury

  NCT06622239

  Not yet recruitingInterventionalPhase 2Updated May 22, 2026
• Evaluation of Naltrexone as a Treatment for Self-injurious Behavior

  NCT02726035

  WithdrawnInterventionalPhase 4Updated Nov 6, 2017
• Self-Injury: Diagnosis and Treatment

  NCT00065936

  Unknown statusInterventionalPhase 3Updated Jun 24, 2005
• Naltrexone Implants as Relapse Prevention

  NCT00269607

  TerminatedInterventionalPhase 2Phase 3Updated Dec 11, 2013
• Naltrexone Implants as an Aid in Preventing Relapse Following Inpatient Treatment for Opioid Addiction

  NCT00521157

  CompletedInterventionalPhase 2Phase 3Updated May 5, 2009
• Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects

  NCT00829777

  CompletedInterventionalPhase 1Updated Sep 16, 2009

ClinicalTrials.gov ID

NCT07641283

Lead Sponsor

Seoul National University HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

150Estimated

Last Update Posted

Jun 11, 2026Actual

Start Date

Jun 2026Estimated

Primary Completion Date

Dec 2027Estimated

Completion Date

Jun 2028Estimated

Official Title

A Randomized, Double-Blinded Clinical Trial to Evaluate the Effectiveness of Naltrexone in Improving Nonsuicidal Self-Injurious Behavior

Brief Summary

This randomized, double-blinded, placebo-controlled clinical trial aims to evaluate the efficacy and safety of naltrexone in reducing nonsuicidal self-injurious behavior among individuals with nonsuicidal self-injury. Participants will be randomly assigned to receive either naltrexone plus treatment as usual or placebo plus treatment as usual for 6 weeks.

The primary objective is to determine whether naltrexone reduces the frequency of nonsuicidal self-injurious behavior compared with placebo. Secondary objectives include evaluating changes in clinical severity, suicidal ideation, self-injury-related urges, ecological momentary assessment measures, and safety outcomes.

Detailed Description

Nonsuicidal self-injury is defined as the intentional destruction of one's own body tissue without suicidal intent. It is clinically important because it is associated with emotional dysregulation, impulsivity, psychiatric comorbidity, and increased risk of future suicidal behavior. However, evidence-based pharmacological treatments specifically targeting nonsuicidal self-injurious behavior remain limited.

Naltrexone is an opioid receptor antagonist that has been suggested to reduce repetitive self-injurious behaviors by modulating endogenous opioid-related reinforcement mechanisms. This study will investigate whether naltrexone is effective in reducing nonsuicidal self-injurious behavior in a randomized, double-blinded, placebo-controlled design.

A total of 150 participants will be enrolled across multiple study sites. Eligible participants will be randomly assigned in a 1:1 ratio to either the naltrexone group or the placebo group. The intervention period will last 6 weeks, with clinical evaluations conducted at baseline and every 2 weeks thereafter. Smartphone-based ecological momentary assessment will also be used to monitor self-injurious urges, mood states, and related behavioral variables during the study period.

Safety will be assessed throughout the study through adverse event monitoring, assessment of suicidal ideation and behavior, laboratory testing, urine testing, and electrocardiography according to the study schedule.

• Nonsuicidal Self-Injury
• Self-Injurious Behavior

• Naltrexone 50mg (Whanin Naltrexone Tab. 50mg)
• Placebo

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Participants must meet all of the following criteria:

  1. Individuals aged 16 years or older.
  2. Individuals with clinically significant nonsuicidal self-injurious behavior.
  3. Individuals who are able to understand the study procedures and provide written informed consent. For minors, consent from a legal guardian and assent from the participant will be obtained according to applicable regulations.
  4. Individuals who are able to comply with study procedures, including clinical visits, medication administration, and study assessments.
  5. Women of childbearing potential must have a negative urine pregnancy test at screening and agree to use appropriate contraception during the study period.

Exclusion Criteria:

• Participants meeting any of the following criteria will be excluded:

  1. Current serious suicidal ideation or high suicide risk, as determined by the investigator.
  2. Current opioid use, opioid dependence, or use of opioid-containing medications.
  3. Current use of opioid antagonists or medications that may interact with naltrexone, including methadone or buprenorphine.
  4. Use of naltrexone within 1 week before screening.
  5. Positive naloxone challenge test or positive urine opioid test, if applicable.
  6. Known hypersensitivity to naltrexone or any component of the investigational product.
  7. Active liver disease, active hepatitis, or clinically significant hepatic impairment.
  8. Clinically significant renal impairment.
  9. Pregnancy or breastfeeding.
  10. Intellectual disability, organic brain disorder, or other condition that may interfere with the participant's ability to understand study procedures or complete assessments.
  11. Inability to read or write Korean sufficiently to complete study assessments.
  12. Documented prior non-response to naltrexone for nonsuicidal self-injury, as judged by the investigator.
  13. Any other clinically significant medical or psychiatric condition that, in the opinion of the investigator, would make participation inappropriate or unsafe.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Seoul National University HospitalOTHER

Collaborators

Asan Medical CenterOTHER

Uijeongbu Eulji University HospitalOTHER

dbwls14615@naver.com+821081194386